SSY GROUP (02005) has obtained the drug production registration certificate for the sodium bicarbonate injection solution in ampoules (10ml: 0.84g) related to the State Food and Drug Administration.
Shi Si Pharmaceutical Group (02005) released an announcement that the group has obtained the relevant approval from the China National Medical Products Administration regarding ampoule packaging...
SSY GROUP (02005) announced that the group has obtained the drug production registration certificate for sodium hydrogen carbonate injection in ampoule packaging (10ml: 0.84g) from the China National Medical Products Administration. This drug belongs to the category 3 of chemical drugs and is considered to have passed consistency evaluation.
Sodium hydrogen carbonate injection in ampoule packaging is mainly used to treat metabolic acidosis, alkalinization of urine, and intravenous infusion for poisoning by certain drugs.
Related Articles
WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.
ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.
DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.
ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.
DL Holdings GP (01709): Purchased 2.152 million shares under the restricted stock incentive plan for the year 2025.
